Table 7.
Laboratory parameters, somatic anomalies and clinical features differentiating 33 women with Turner syndrome treated with growth hormone in childhood; GH therapy initiation before the age of 12 (GH < 12 years) or later (GH ≥ 12 years). V – absolute values and (%) – percentages. Superscript P-value statistically significant compared to TS women not treated with growth hormone in childhood.
| Parameters [normal ranges] |
GH < 12 (n = 12) |
GH ≥ 12 (n = 21) |
GH < 12 vs.GH ≥ 12 P - value |
|---|---|---|---|
| Height (cm) | 147.1 ± 5.90.0387 | 149 ± 6.90.0009 | 0.5474 |
| BMI (kg/m2) | 21.6 ± 3.70.0036 | 21.7 ± 3.80.0036 | 0.9193 |
| Age of start GH treatment | 8.25 ± 1.5 | 14.4 ± 1.9 | 0.000 |
| FSH (IU/L) [2.8–11.3] | 52.4 ± 310.0452 | 48.9 ± 240.0111 | 0.7255 |
| E2 (pmol/L) [66–884] | 152 ± 158 | 153 ± 1750.0329 | 0.9923 |
| Cholesterol (mmol/L) [3.9–5] | 4.43 ± 0.720.0234 | 4.69 ± 0.97 | 0.4266 |
| HDL (mmol/L) [>1] | 1.3 ± 0.3 | 1.4 ± 0.4 | 0.4172 |
| LDL (mmol/L) [<3] | 3 ± 0.51 | 3 ± 0.92 | 0.9902 |
| TG (g/L) [0.4–1.7] | 0.81 ± 0.40.059 | 0.95 ± 0.5 | 0.4189 |
| Creatinine (µmol/L) [60–130] | 64 ± 11.5 | 60.3 ± 9.5 | 0.2329 |
| Red blood cells (1012/L) [4.2–5] | 4.77 ± 0.24 | 4.59 ± 0.29 | 0.0812 |
| Thrombocytes (109/L) [150–300 | 252.3 ± 34.6 | 215.1 ± 55.60.0087 | 0.0453 |
| V (%) | V (%) | ||
| Retrognathism | 9 75 | 17 810.0397 | 0.6849 |
| Dense eyebrows, long eyelashes | 5 41.70.0174 | 9 42.90.0039 | 0.9465 |
| Fingernail anomalies | 8 66.7 | 14 66.7 | 1 |
| Ingrowing nails | 4 33.3 | 8 38.10.0426 | 0.7694 |
| Blood pressure ≥ 140/90 mmHg | 1 8.3 | 3 14.3 | 0.6114 |
| Urinary system malformations | 4 33.3 | 6 28.6 | 0.7775 |
| HRT | 5 41.7 | 15 71.4 | 0.093 |